Lazard Asset Management LLC Takes Position in Cellebrite DI Ltd. $CLBT

Lazard Asset Management LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 154,863 shares of the company’s stock, valued at approximately $2,134,000.

Several other institutional investors also recently modified their holdings of CLBT. Roubaix Capital LLC raised its position in Cellebrite DI by 108.1% during the 1st quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock worth $4,178,000 after purchasing an additional 157,536 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Cellebrite DI by 33.9% in the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after buying an additional 545,334 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Cellebrite DI by 28.6% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock worth $24,341,000 after acquiring an additional 300,000 shares during the last quarter. Weiss Asset Management LP raised its position in shares of Cellebrite DI by 3,485.3% during the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after acquiring an additional 1,846,851 shares during the last quarter. Finally, UBS Group AG lifted its stake in shares of Cellebrite DI by 99.0% in the fourth quarter. UBS Group AG now owns 376,376 shares of the company’s stock worth $6,786,000 after acquiring an additional 187,220 shares during the period. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $14.75 on Monday. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98. The stock’s 50-day moving average is $14.33 and its 200 day moving average is $14.15. The firm has a market cap of $3.68 billion, a price-to-earnings ratio of 52.68, a PEG ratio of 1.83 and a beta of 1.18.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Needham & Company LLC reduced their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. DA Davidson began coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target for the company. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Insiders Place Their Bets

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas E. Hogan sold 103,188 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the transaction, the chief executive officer owned 590,777 shares in the company, valued at $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 158,191 shares of company stock worth $2,479,438. 5.70% of the stock is owned by corporate insiders.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.